Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin

Masaru Hirano, Kazuya Maeda, Soichiro Matsushima, Yoshitane Nozaki, Hiroyuki Kusuhara, and Yuichi Sugiyama

Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan

Received April 20, 2005; accepted June 13, 2005

ABSTRACT

Pitavastatin, a novel potent 3-hydroxymethylglutaryl coenzyme A reductase inhibitor, is distributed selectively to the liver and excreted into bile in unchanged form in rats. We reported previously that the hepatic uptake is mainly mediated by organic anion transporting polypeptide (OATP) 1B1, whereas the biliary excretion mechanism remains to be clarified. In the present study, we investigated the role of breast cancer resistance protein (BCRP) in the biliary excretion of pitavastatin. The ATP-dependent uptake of pitavastatin by human and mouse BCRP-expressing membrane vesicles was significantly higher compared with that by control vesicles with $K_m$ values of 5.73 and 4.77 μM, respectively. The biliary excretion clearance of pitavastatin in Bcrp1(−/−) mice was decreased to one-tenth of that in control mice. The biliary excretion of pitavastatin was unchanged between control and Eisai hyperbilirubinemic rats, indicating a minor contribution of multidrug resistance-associated protein (Mrp) 2. These data suggest that the biliary clearance of pitavastatin can be largely accounted for by BCRP in mice. In the case of humans, transcellular transport of pitavastatin was determined in the Madin-Darby canine kidney II cells expressing OATP1B1 and human canalicular efflux transporters. A significant basolateral-to-apical transport of pitavastatin was observed in OATP1B1/MDR1 and OATP1B1/MDR1/MRP2 double transfectants as well as OATP1B1/BCRP double transfectants, implying the involvement of multiple transporters in the biliary excretion of pitavastatin in humans. This is in contrast to a previous belief that the biliary excretion of statins is mediated mainly by MRPs.

The liver plays an important role in the excretion of xenobiotics, including many kinds of drugs. A number of reports have shown that several kinds of transporters are expressed on the canalicular membrane in the liver for the efficient elimination of drugs via the bile (Chandra and Brouwer, 2004). It has been generally accepted that transport of various organic anions across the canalicular membrane is mainly mediated by multidrug resistance-associated protein 2 (MRP2/ABCC2), whereas the bile salt export pump (BSEP/ABCB11) exclusively accepts bile acids, and multidrug resistance protein (P-glycoprotein, MDR1/ABCB1) can transport relatively hydrophobic neutral or cationic compounds (Chandra and Brouwer, 2004). However, several reports have shown that some anionic drugs can also be recognized by BSEP and MDR1 (Cvetkovic et al., 1999; Hirano et al., 2005), suggesting that multiple transport mechanisms are involved in the biliary excretion of organic anions.

Moreover, breast cancer resistance protein (BCRP/ABCG2) has been cloned recently and can accept various kinds of organic anions, especially sulfated conjugates of steroids and xenobiotics (Allikmets et al., 1998; Suzuki et al., 2003). Because BCRP is expressed on the bile canalicular membrane of hepatocytes as well as the brush-border membrane of enterocytes, trophoblast cells in placenta, and the apical membrane of lactiferous ducts in the mammary gland (Maliepaard et al., 2001), BCRP must also be considered as one of the routes for the biliary excretion of organic anions. Current evidence indicates that BCRP contributes to the membrane transport of some substrates, such as intestinal absorption and transfer to breast milk (Jonker et al., 2000, 2002; Adachi et al., 2003), suggesting that multiple transport mechanisms are involved in the biliary excretion of organic anions.

ABBREVIATIONS: MRP (Mrp), multidrug resistance-associated protein; OATP (Oatp), organic anion transporting polypeptide; BCRP (Bcrp), breast cancer resistance protein; BSEP (Bsep), bile salt export pump; MDR (Mdr), multidrug resistance protein; HEK, human embryonic kidney; MDMK, Madin-Darby canine kidney; HMCOa3, 3-hydroxy-3-methylglutaryl-coenzyme A; E17βG, 17β-estradiol-17β-0-glucuronide; EHBR, Eisai hyperbilirubinemic rat; LC/MS, high-performance liquid chromatography/mass spectrometry; GFP, green fluorescent protein; SNP, single nucleotide polymorphism; TS, Tris-HCl and sucrose; PE, polyethylene.
2005a). Regarding the involvement of BCRP in biliary excretion, some reports have demonstrated that the biliary excretion of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine and nitrofurantoin is almost impaired in Bcrp1(−/−) mice (van Herwaarden et al., 2003; Merino et al., 2005a) and that the biliary excretion of topotecan and cimetidine is also mainly regulated by Bcrp, considering the gender difference in the hepatic expression level of Bcrp and the plasma concentration profiles (Merino et al., 2005b). In addition, it has been demonstrated that certain kinds of single-nucleotide polymorphisms (SNPs) in BCRP and inhibition of BCRP-mediated transport by some compounds may alter its function and the pharmacokinetics of some drugs in vitro (Imai et al., 2002; Zamber et al., 2003; Kondo et al., 2004) as well as in vivo (Krujitch et al., 2002; Sparreboom et al., 2004). Therefore, the pharmacokinetics of several important compounds are regulated mainly by BCRP.

Pitavastatin is a highly potent inhibitor of 3-hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis (Kajinami et al., 2003). Pitavastatin causes a significant reduction in not only serum total cholesterol and low-density lipoprotein cholesterol but also triglyceride levels (Stein et al., 1998). It has been demonstrated that [14C]pitavastatin is distributed selectively to the liver in rats with a liver-to-plasma concentration ratio of more than 50 (Kimata et al., 1998). We demonstrated previously that pitavastatin is taken up into human hepatocytes mainly by OATP1B1 (OATP2/OATP-C) (Hirano et al., 2004). Then, because it is scarcely metabolized in human liver microsomes (Fujino et al., 2003), pitavastatin is supposed to be excreted into bile in unchanged form (Kojima et al., 1998). However, the biliary transport mechanism of pitavastatin has not been clarified yet. So far, Fujino et al. (2002) have demonstrated that after intravenous bolus administration of pitavastatin, its plasma concentration and biliary excretion in Eisai hyperbilirubinemic rats were comparable with those in Sprague-Dawley rats and that the plasma and brain concentrations of pitavastatin in mdr1a1b knockout mice are not different from those in control mice. In addition, we have already shown that pitavastatin is not a substrate of rat and human BSEP (Hirano et al., 2005). These results suggest that BSEP, MRP2, and MDR1 do not make a major contribution to the biliary excretion of pitavastatin.

In the present study, to demonstrate the involvement of BCRP in the biliary excretion of pitavastatin, we examined the transport of pitavastatin by transporter expression systems and observed the biliary excretion clearance of pitavastatin in transporter-deficient animals. Moreover, to check whether other statins could be substrates of BCRP or not, we performed a transport study using BCRP-expressing membrane vesicles.

### Materials and Methods

**Animals.** Male Bcrp1(−/−) and wild-type FVB mice (16–18 weeks old) were used in the present study (Jonker et al., 2002). Male Sprague-Dawley rats (7–8 weeks old) and EHBRs (7–8 weeks old) were purchased from Nippon SLC (Shizuoka, Japan). All animals were maintained under standard conditions with a reverse dark-light cycle and were treated humanely. Food and water were available ad libitum. The studies reported in this manuscript were carried out in accordance with the guidelines provided by the Institutional Animal Care Committee (Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan).

**Materials.** Pitavastatin, monoclonal antibody (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinoxyl]-3,5-dihydroxy-6-heptanoic acid was synthesized by Nissan Chemical Industries (Chiba, Japan). [3H]Pitavastatin (16.0 Ci/mmol) and [3H]cerivastatin (4.86 Ci/mmol) were synthesized by Amersham Biosciences UK, Ltd. (Little Chalfont, Buckinghamshire, UK) and Hartmann Analytical GmbH (Braunschweig, Germany), respectively. [3H]Pravastatin (44.6 Ci/mmol), [3H]lovastatin (45.7 mCi/mmol), and [3H]rosuvastatin (79 Ci/mmol) were supplied by Sankyo Co., Ltd. (Tokyo, Japan). Novartis Pharma K.K. (Basel, Switzerland), and AstraZeneca PLC (London, UK), respectively. Other unlabeled HMG-CoA reductase inhibitors (atorvastatin, cerivastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin acid) were donated by Kowa Co., Ltd. (Tokyo, Japan). [3H]17β-Estradiol-17β-d-glucuronide (E17βG) and [3H]estrone-3-sulfate (45 and 46 Ci/mmol, respectively) were purchased from PerkinElmer Life and Analytical Sciences (Boston, MA). Unlabeled E17βG and estrone-3-sulfates were purchased from Sigma-Aldrich (St. Louis, MO). All chemicals were of analytical grade and were commercially available.

**Cell Culture.** Human BCRP-, mouse Bcrp-, or green fluorescent protein (GFP)-transfected HEK293 cells (Kondo et al., 2004) and MDCK II single- and double-transfected cells expressing human OATP1B1, MDR1, MRP2, or BCRP (Matsushima et al., 2005) and rat Oatp1b2 or Mrp2 (Sasaki et al., 2004) were grown in Dulbecco's modified Eagle's medium low glucose (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Sigma-Aldrich), 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C with 5% CO2 and at 95% humidity.

**Construction and Infection of Recombinant Adenovirus and the Membrane-Vesicle Preparation.** Details of the procedure for producing recombinant adenovirus containing human BCRP, mouse Bcrp, and GFP have been described previously (Kondo et al., 2004). Membrane vesicles were prepared from BCRP and GFP-transfected HEK293 cells according to the method described previously (Kondo et al., 2004). For the preparation of the isolated membrane vesicles, HEK293 cells cultured in a 15-cm dish were infected by recombinant adenovirus containing human and mouse BCRP cDNA (multiplicity of infection = 10). As a negative control, cells were infected with GFP (multiplicity of infection = 10). Cells were harvested 48 h after infection, and then the membrane vesicles were isolated from 1 to 2 × 10⁸ cells using a standard method described previously in detail (Muller et al., 1994). In brief, cells were diluted 40-fold with hypotonic buffer (1 mM Tris-HCl and 0.1 mM EDTA, pH 7.4, at 37°C) and stirred gently for 1 h on ice in the presence of 2 mM phenylmethylsulfonyl fluoride, 5 μg/ml leupeptin, 1 μg/ml pepstatin, and 5 μg/ml aprotinin. The cell lysate was centrifuged at 100,000 g for 30 min at 4°C, and the resulting pellet was suspended in 10 ml of isotonic TS buffer (10 mM Tris-HCl and 250 mM sucrose, pH 7.4 at 4°C) and homogenized using a Dounce B homogenizer (glass/glass, tight pestle, 30 strokes). The crude membrane fraction was layered on top of 38% (w/v) sucrose solution in 5 mM Tris-HEPES, pH 7.4, at 4°C, and centrifuged in Beckman SW41 rotor centrifuged at 280,000 g for 60 min at 4°C. The turbid layer at the interface was collected, diluted to 23 ml with TS buffer, and centrifuged at 100,000 g for 30 min at 4°C. The resulting pellet was suspended in 400 μl of TS buffer. Vesicles were formed by passing the suspension 30 times through a 27-gauge needle using a syringe. The membrane vesicles were finally frozen in liquid nitrogen and stored at −80°C until use. Protein concentrations were determined by the Lowry method, and bovine serum albumin was used as a standard.

**Transport Studies with Membrane Vesicles.** The transport studies were performed using a rapid filtration technique (Hirohashi et al., 1999). In brief, 15 μl of transport medium (10 mM Tris-HCl, 250 mM sucrose, and 10 mM MgCl₂, pH 7.4) containing radiolabeled compounds, with or without unlabeled substrate, was preincubated...
at 37°C for 3 min and then rapidly mixed with 5 μl of membrane vesicle suspension (5 μg of protein). The reaction mixture contained 5 mM ATP or AMP along with the ATP-regenerating system (10 mM creatine phosphate and 100 μg/μl creatine phosphokinase). The transport reaction was terminated by the addition of 1 ml of ice-cold buffer containing 10 mM Tris-HCl, 250 mM sucrose, and 0.1 M NaCl, pH 7.4. The stopped reaction mixture was filtered through a 0.45-μm hemagglutinin filter (Millipore Corporation, Billerica, MA) and then washed twice with 5 ml of stop solution. Radioactivity retained on the filter was determined in a liquid scintillation counter (LS6000SE; Beckman Coulter, Inc., Fullerton, CA) after the addition of scintillation cocktail (Clear-sol I; Nacalai Tesque, Tokyo, Japan).

**Transcellular Transport Study.** Transfected MDCK II cells were seeded in 24-well plates at a density of 1.4 × 10^5 cells/well and were cultured with 10 mM sodium butyrate for 24 h before the transport study (Sasaki et al., 2002). Krebs-Henseleit buffer consisted of 142 mM NaCl, 23.8 mM Na_2CO_3, 4.83 mM KCl, 0.96 mM KH_2PO_4, 1.20 mM MgSO_4, 12.5 mM HEPES, 5 mM glucose, and 1.53 mM CaCl_2 adjusted to pH 7.4. The experiments were initiated by replacing the medium on either the apical or basal side of the cell layer with complete medium containing tritium-labeled and unlabeled E_22%β or pitavastatin (0.1 μM). The cells were incubated at 37°C, and aliquots of medium were taken from each compartment at designated time points. Radioactivity in 100 μl of medium was measured in a liquid scintillation counter (LS6000SE; Beckman Coulter) after the addition of scintillation cocktail (Clear-sol I; Nacalai Tesque). At the end of the experiments, the cells were washed three times with 1.5 ml of ice-cold Krebs-Henseleit buffer and solubilized in 450 μl of 0.2 N NaOH. After the addition of 225 μl of 0.4 N HCl, 600-μl aliquots were transferred to scintillation vials. Aliquots (50 μl) of cell lysate were used to determine protein concentrations as described above.

**Kinetic Analysis.** Ligand uptake was normalized in terms of the amount of membrane protein and expressed as the uptake volume ([μl/mg protein], given as the amount of radioactivity associated with the cells [dpm/mg protein]) divided by its concentration in the incubation medium [dpm/μl]. The ATP-dependent uptake of ligands via BCRP was calculated by subtracting the ligand in the presence of AMP from that in the presence of ATP. Kinetic parameters were obtained using the equation ν = (V_max × S)/(K_m + S), where ν is the uptake velocity of the substrate (in picomoles per minute per milligram of protein), S is the substrate concentration in the medium (in micromolars), K_m is the Michaelis constant (in micromolars), and V_max is the maximum uptake velocity (in picomoles per minute per milligram of protein). The Damping Gauss Newton Method algorithm was used with a MULTI program (Yamaoka et al., 1981) to perform nonlinear least-squares data fitting. Inhibition constants (K_i) of a series of compounds were calculated with the use of the following equation (if the substrate concentration was much lower than the K_m value): CL(+/−) = CL(1 + I/K_i), where CL represents the uptake clearance in the absence of inhibitor, CL(+/−) represents the uptake clearance in the presence of inhibitor, and I represents the concentration of the inhibitor. When fitting the data to determine the K_i value, the input data were weighed as the reciprocal of the observed values.

**In Vivo Infusion Study in Rats.** Male Sprague-Dawley rats and EHRBS weighing approximately 250 to 300 g were used for these experiments. Under pentobarbital anesthesia (30 mg/kg), the femoral vein was cannulated with a polyethylene catheter (PE-50) for the injection of [3H]pitavastatin. The bile duct was cannulated with a polyethylene catheter (PE-10) for bile collection. The rats received a constant infusion of pitavastatin at a dose of 72 μg/kg/h after a bolus intravenous administration of 0.25 mg/kg. Blood samples were collected from the jugular vein. Bile was collected in preweighed test tubes at 30-min intervals throughout the experiment. Plasma was prepared by centrifugation of the blood samples (10,000g, Microfuge; Beckman Coulter). The rats were killed after 210 min, and the entire liver was excised immediately. Then the liver was weighed and minced, and subsequently 200 μl of hydroperoxide and 400 μl of isopropanol were added to approximately 200 mg of liver. This was incubated at 55°C for 4 to 6 h after the addition of 2 ml of soluene (PerkinElmer Life and Analytical Sciences) to dissolve the tissues, and then the radioactivity was determined in a liquid scintillation counter after the addition of scintillation cocktail.

**In Vivo Infusion Study in Mice and Quantification of Pitavastatin by LC/MS.** Male FVB and B6C3F1 mice weighing approximately 25 to 33 g were used throughout these experiments. Under pentobarbital anesthesia (30 mg/kg), the jugular vein was cannulated with a polyethylene catheter (PE-10) for the injection of pitavastatin. The bile duct was cannulated with a polyethylene catheter (SP-8) for bile collection. The mice received a constant infusion of pitavastatin at a dose of 300 μg/kg/h. Blood samples were collected from the opposite jugular vein. Bile was collected in preweighed test tubes at 15-min intervals throughout the experiments. Plasma was prepared by centrifugation of the blood samples. The mice were killed after 150 min, and the entire liver, kidney, brain, and skeletal muscle were excised immediately. The tissues were weighed and stored at −80°C until quantification. Portions of liver, kidney, brain, and skeletal muscle were added to five volumes of physiological saline (w/v) and homogenized. Plasma (10 μl), bile (1 μl), or tissue homogenate (10 or 100 μl) was deproteinized with 200 μl of methanol containing the internal standard (40 ng/ml atorvastatin), followed by centrifugation at 4°C and 10,000g for 10 min. The supernatant (100 μl) was mixed with 50 μl of water and subjected to high-performance liquid chromatography (Waters 2695; Waters, Milford, MA). The LC/MS analysis of pitavastatin was performed using an Inertsil ODS-3 column (50 × 2.1 mm; particle size, 5 μm) (GL Sciences, Tokyo, Japan). The mobile phase consisted of methanol/ammonium formate buffer, pH 4 = 7.3 (v/v), and the flow rate was 0.7 ml/min. The MS instrument used for this work was a QZ micromass (Waters) equipped with a Z-spray source; it was operated in the positive-ion electrospray ionization mode. The Z-spray desolvation temperature, capillary voltage, and cone voltage were 350°C, 3400 V, and 40 V, respectively. The m/z monitored for pitavastatin and atorvastatin was 422.3 and 559.0, respectively. No chromatographic interference was found for pitavastatin and atorvastatin in extracts from blank plasma, bile, and tissue homogenates. The retention times of pitavastatin and atorvastatin were 1.2 and 1.1 min, respectively. The detection limits for pitavastatin were 5, 2000, 100, 5, and 5 ng/ml in plasma, bile, liver, kidney, brain, and muscle, respectively.

**Pharmacokinetic Analysis.** Total plasma clearance (CL_total), biliary clearance normalized by circulating plasma (CL_bile,plasma/), and biliary clearance normalized by the liver concentration (CL_bile,liver) were calculated from the equations CL_total = I/C_s,plasma, CL_bile,plasma = V_bile/C_s,plasma, and CL_bile,liver = V_bile/C_s,liver, where I, C_s,plasma, V_bile, and C_s,liver represent the infusion rate (in micrograms per minute per kilogram), plasma concentrations at steady state (in nanograms per milliliter), biliary excretion rate at steady state (in micrograms per minute per kilogram), and hepatic concentration at steady state (in nanograms per milliliter), respectively. In rats, C_s,plasma was determined as the mean value of the plasma [3H]pitavastatin concentrations at 60, 90, 120, 150, 180, and 210 min. V_bile was determined as the mean value of the biliary excretion rate of [3H]pitavastatin from 60 to 90 min, from 90 to 120 min, from 120 to 150 min, from 150 to 180 min, and from 180 to 210 min. In mice, C_s,plasma was determined as the mean value of the plasma unlabeled pitavastatin concentrations at 90, 120, and 150 min. V_bile was determined as the mean value of the biliary excretion rate of unlabeled pitavastatin from 90 to 105 min, from 105 to 120 min, from 120 to 135 min, and from 135 to 150 min. C_s,liver was determined as the hepatic pitavastatin concentration at the end of the in vivo experiment. To calculate C_s,liver, the specific gravity of the liver was assumed to be unity. Thus, the amount in the liver (nanograms per gram of liver) can be regarded as the hepatic concentration (nanograms per gram), and the units of CL_bile,liver are in milliliters per minute per kilogram.
Results

ATP-Dependent Uptake of [3H]Pitavastatin into BCRP-Expressing Membrane Vesicles. The time profiles and Eadie-Hofstee plots for the uptake of [3H]pitavastatin by BCRP-expressing membrane vesicles are shown in Fig. 1. The uptake of [3H]pitavastatin into membrane vesicles from human and mouse BCRP-transfected HEK293 cells was markedly stimulated by ATP but not that into GFP-transfected control cells (Fig. 1, A and B). The concentration-dependence of human and mouse BCRP-mediated ATP-dependent uptake of pitavastatin is shown in Fig. 1, C and D. The $K_m$ and $V_{max}$ values for the ATP-dependent uptake of pitavastatin were $5.73 \pm 1.52$ nM and $1106 \pm 79$ pmol/min/mg protein by human BCRP and $4.77 \pm 0.50$ nM and $881 \pm 20$ pmol/min/mg protein by mouse Bcrp, respectively.

Uptake of Other Statins into BCRP-Expressing Membrane Vesicles. Uptake of other statins into human and mouse BCRP-expressing membrane vesicles was observed (Fig. 2). We did not see any significant ATP-dependent uptake of cerivastatin and fluvastatin by mouse Bcrp-expressing membrane vesicles compared with GFP-transfected vesicles, whereas human BCRP significantly recognized all of the statins we tested (cerivastatin, fluvastatin, pitavastatin, pravastatin, and rosuvastatin) as a substrate (Fig. 2, A–E). Estrone-3-sulfate (0.1 nM), which was a positive control compound for BCRP-mediated transport, was accepted as a substrate of both human and mouse BCRP (Fig. 2F). The $K_m$ value of estrone-3-sulfate by mouse Bcrp was $16.4 \pm 3.0$ nM (data not shown).

Inhibitory Effects of Statins on the ATP-Dependent Uptake of [3H]Estrone-3-sulfate into Human and Mouse BCRP-Expressing Membrane Vesicles. The inhibitory effects of statins on the ATP-dependent uptake of [3H]estrone-3-sulfate by human and mouse BCRP-expressing membrane vesicles were observed. All of the statins except for pravastatin ($\sim 300$ nM), inhibited the ATP-dependent uptake of [3H]estrone-3-sulfate by human and mouse BCRP in a dose-dependent manner. The $K_i$ values of statins for human and mouse BCRP are summarized in Table 1.

Transcellular Transport of Pitavastatin across Double Transfectants. Transcellular transport of pitavastatin across double-transfected MDCK II monolayers expressing uptake transporter (OATP1B1) and efflux transporter (MDR1, MRP2, or BCRP) was compared with that across the single-transfected monolayer and the vector-transfected con-
control monolayer. In the case of humans, as shown in Fig. 3, a symmetrical flux of pitavastatin was observed across the control, MDR1-, MRP2-, and BCRP-expressing MDCK II monolayer. The basal-to-apical flux of pitavastatin across the OATP1B1-expressing monolayer was approximately twice that in the opposite direction, whereas the basal-to-apical flux of pitavastatin was approximately 15, 110, and 230 times higher than that in the opposite direction in OATP1B1/ MRP2, OATP1B1/BCRP, and OATP1B1/MRP2 double-transfected cells, respectively. In addition, transcellular transport of pitavastatin across double-transfected MDCK II monolayers expressing rat Oatp1b2 and Mrp2 was also compared with that across the Oatp1b2 or Mrp2 single-transfected monolayer and the vector-transfected control monolayer. The basal-to-apical flux of pitavastatin was 2.4 times higher than that in the opposite direction in the Oatp1b2/Mrp2 double-transfected cells, although a smaller vectorial transport was observed even in the Oatp1b2-expressing monolayer (Fig. 4). In both rats and humans, we checked the transcellular transport velocity in the presence of AMP from that in the presence of ATP. The values are expressed as mean ± computer-calculated S.D. (n = 3).

Table 1
Inhibitory effects of statins on the ATP-dependent uptake of [3H]estrone-3-sulfate by human BCRP- and mouse Bcrp-expressing membrane vesicles

<table>
<thead>
<tr>
<th>Statins</th>
<th>hBCRP</th>
<th>mBcrp</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atorvastatin</td>
<td>14.3 ± 1.9</td>
<td>17.6 ± 1.7</td>
</tr>
<tr>
<td>Cetavastatin</td>
<td>18.1 ± 2.5</td>
<td>30.1 ± 6.3</td>
</tr>
<tr>
<td>Fluvastatin</td>
<td>5.43 ± 0.37</td>
<td>8.62 ± 1.86</td>
</tr>
<tr>
<td>Pitavastatin</td>
<td>2.92 ± 0.35</td>
<td>6.00 ± 0.71</td>
</tr>
<tr>
<td>Pravastatin</td>
<td>&gt;300 µM</td>
<td>&gt;300 µM</td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>15.4 ± 2.4</td>
<td>10.3 ± 0.6</td>
</tr>
<tr>
<td>Simvastatin acid</td>
<td>18.0 ± 4.3</td>
<td>24.9 ± 3.8</td>
</tr>
</tbody>
</table>

Plasma, Liver Concentration and Biliary Excretion Profiles at Steady State in Sprague-Dawley Rats and EHBRRs. It has been reported that pitavastatin is not significantly metabolized in rats, and 70% of the excreted amount in bile can be detected in unchanged form (Fujino et al., 2002). Therefore, we used [3H]pitavastatin in rats in an in vivo study to examine the involvement of Mrp2 in the biliary excretion of pitavastatin. The plasma concentration of pitavastatin reached a plateau at 60 min during constant infusion after a bolus intravenous administration. The biliary excretion rate (Vₜₐₜₑ), the steady-state plasma concentration (Cₛₚ, plasma), and total clearance (CLₜₒₜₐₑₜ) values of pitavastatin in EHBRRs were almost the same as those in normal rats (Fig. 5 and Table 2). The concentration of pitavastatin and the Kᵢ value in the liver at steady state in EHBRRs were lower than those in normal rats, and the CLₜᵢₜₑ, plasma and CLₜᵢₜₑ, liver values in EHBRRs were slightly higher than those in normal rats, although the differences were not statistically significant (Fig. 5).

Plasma, Tissue Concentration, and Biliary Excretion Profiles at Steady State in FVB and Bcrp1(−/−) Mice. The plasma concentration of pitavastatin reached a plateau at 90 min during constant infusion (Fig. 6). The Vₜₐₜₑ of parent pitavastatin in Bcrp1(−/−) mice was much lower than that in control mice, whereas the Cₛₚ, plasma and CLₜₒₜₐₑₜ values of pitavastatin in Bcrp1(−/−) mice did not differ from those in normal mice (Table 3). The Kᵢ values of pitavastatin in the kidney, brain, and skeletal muscle as well as the liver (Table 3) at steady state were similar in control and Bcrp1(−/−) mice (Kᵢ value for kidney, 1.41 ± 0.10 and 1.48 ± 0.12 ng/g; for brain, 0.0308 ± 0.0027 and 0.0322 ± 0.0070 ng/g; and for skeletal muscle, 0.0985 ± 0.0075 and 0.0960 ± 0.0061 ng/g in wild-type and Bcrp1(−/−) mice, respectively).

Discussion
Pitavastatin, a new potent inhibitor of HMG-CoA reductase, is scarcely metabolized in humans and is believed to be excreted into the bile in intact form. In the present study, we concentrated on a new candidate transporter, BCRP, for the biliary excretion of pitavastatin.

Fig. 3. Time profiles for the transcellular transport of [3H]pitavastatin across MDCK II monolayers expressing human transporters. Transcellular transport of [3H]pitavastatin (0.1 µM) across MDCK II monolayers expressing OATP1B1 (B), BCRP (C), MDR1 (D), Mrp2 (E), both OATP1B1 and BCRP (F), both OATP1B1 and MDR1 (G), and both OATP1B1 and Mrp2 (H) was compared with that across the vector-transfected control MDCK II monolayer (A). ○ and ● represent the transcellular transport in the apical-to-basal and basal-to-apical direction, respectively. Each point represents the mean ± S.E. (n = 3). Where vertical bars are not shown, the S.E. values are within the limits of the symbols.
ATP-dependent uptake of pitavastatin in human and mouse BCRP-expressing membrane vesicles was observed (Fig. 1). The $K_i$ value of pitavastatin for human BCRP (5.73 $\mu$M) was almost the same as that for mouse Bcrp (4.77 $\mu$M), and these $K_i$ values were similar to that of estrone-3-sulfate, which is a well-known substrate of human BCRP (Suzuki et al., 2003), indicating that pitavastatin is also a good substrate of BCRP. Regarding other statins, as shown in Table 1, no species difference in the $K_i$ value of each statin for the BCRP-mediated uptake of estrone-3-sulfate was observed between humans and mice. The inhibition potency of statins, except for pravastatin, was almost identical, whereas pravastatin could not inhibit the BCRP-mediated transport of estrone-3-sulfate up to 300 $\mu$M. On the other hand, all statins we tested could be substrates of human BCRP, whereas four of them were also substrates of mouse Bcrp (Fig. 2). From a pharmacokinetic viewpoint, BCRP could at least partly contribute to the biliary excretion of pravastatin, pitavastatin, and rosuvastatin, which are scarcely metabolized by metabolic enzymes like cytochrome P450 in the liver. On the other hand, in the case of atorvastatin, cerivastatin, and simvastatin, which have been reported to be extensively metabolized by cytochrome P450 enzymes (Garcia et al., 2003), the biliary excretion of their unchanged form via BCRP was considered to be minor in in vivo situations.

To estimate the contribution of each transporter to the biliary excretion of pitavastatin in the in vivo study, the biliary excretion of pitavastatin at steady state was investigated using Mrp2- and Bcrp1-deficient animals. Because pitavastatin was found to be scarcely metabolized in rats (Fujino et al., 2002), the radioactivity would reflect the parent pitavastatin. We confirmed that the plasma concentration and biliary excretion rate of pitavastatin was not changed between Sprague-Dawley rats and EHBRs (Fig. 5 and Table 2), which is consistent with a previous report (Fujino et al., 2002). Therefore, the involvement of Mrp2 in the biliary excretion of pitavastatin is minor. The liver concentration in EHBRs was significantly lower than that in control rats possibly because of the accelerated efflux via the basolateral membrane in the liver caused by the induction of Mrp3 (Ogawa et al., 2000) and the inhibition of hepatic uptake process from the blood by a higher concentration of bilirubin glucuronide in EHBRs (Sathirakul et al., 1993), or by the decrease in the expression levels of transporters responsible for the uptake of pitavastatin.

Biliary excretion of pitavastatin was also observed in Bcrp1(−/−) and control mice. In contrast to humans and rats, pitavastatin is extensively metabolized in mice, so we decided to quantify the unchanged form separately by LC/MS in mice. The biliary excretion clearance of pitavastatin in Bcrp1(−/−) mice was 10 times lower than that in control mice, suggesting that unchanged pitavastatin is excreted into bile mainly by Bcrp. In control mice, the biliary clear-

---

**Fig. 4.** Time profiles for the transcellular transport of [3H]pitavastatin across MDCK II monolayers expressing rat transporters. Transcellular transport of [3H]pitavastatin (0.1 $\mu$M) across MDCK II monolayers expressing Oatp1b2 (B), Mrp2 (C), and both Oatp1b2 and Mrp2 (D) was compared with that across the vector-transfected control MDCK II monolayer (A). ○ and □ represent the transcellular transport in the apical-to-basal and basal-to-apical direction, respectively. Each point represents the mean ± S.E. ($n = 3$). Where vertical bars are not shown, the S.E. values are within the limits of the symbols.

**Fig. 5.** Plasma concentrations and biliary excretion rate of [3H]pitavastatin during constant intravenous infusion into Sprague-Dawley rats and EHBRs. The plasma concentration (A) and biliary excretion rate (B) of total radioactivity were determined during constant intravenous infusion into Sprague-Dawley rats (○) and EHBRs (●). Each point plotted, with its vertical bar, represents the mean ± S.E. of four rats.

**TABLE 2**

Pharmacokinetic parameters of pitavastatin during constant intravenous infusion into Sprague-Dawley (SD) rats and EHBRs

Data represent the mean ± S.E. ($n = 4$).

<table>
<thead>
<tr>
<th></th>
<th>$C_{\text{ss,plasma}}$</th>
<th>$\text{CL}_{\text{total}}$</th>
<th>$\text{CL}_{\text{bile,plasma}}$</th>
<th>$\text{CL}_{\text{bile,liver}}$</th>
<th>Liver Concentration</th>
<th>$K_p$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Eq·ml⁻¹</td>
<td>ml·min⁻¹·kg⁻¹</td>
<td>ml·min⁻¹</td>
<td>ml·min⁻¹</td>
<td>Eq·g⁻¹</td>
<td></td>
</tr>
<tr>
<td>SD rat</td>
<td>195 ± 13</td>
<td>6.26 ± 0.49</td>
<td>4.55 ± 0.13</td>
<td>0.248 ± 0.042</td>
<td>4346 ± 406</td>
<td>23.0 ± 3.6</td>
</tr>
<tr>
<td>EHBR</td>
<td>179 ± 8</td>
<td>6.75 ± 0.34</td>
<td>5.77 ± 0.53</td>
<td>0.399 ± 0.049</td>
<td>2621 ± 139**</td>
<td>14.7 ± 0.8</td>
</tr>
</tbody>
</table>

$\ast \ast P < 0.01$.

$C_{\text{ss,plasma}}$, plasma steady-state concentration (mean of plasma concentration at 210 min); $\text{CL}_{\text{total}}$, total plasma clearance obtained by dividing the infusion rate by $C_{\text{ss,plasma}}$; $\text{CL}_{\text{bile,plasma}}$, biliary clearance normalized by the plasma concentration; $\text{CL}_{\text{bile,liver}}$, biliary clearance normalized by the liver concentration; $K_p$, value obtained by dividing the liver concentration by $C_{\text{ss,plasma}}$ (at 210 min).
accretion normalized by plasma concentration (CL\textsubscript{bile/plasma}) accounted for only 5% of the plasma total clearance (CL\textsubscript{total}), indicating that pitavastatin is mainly excreted into bile as metabolites. Taking extensive metabolism into consideration, it is natural that the plasma and liver concentrations were not different between Bcrp1\((-/-)\) and control mice, even if the biliary clearance of the parent compound was drastically reduced in Bcrp1\((-/-)\) mice. In contrast to mice, pitavastatin is believed to be excreted into the bile in an intact form with only minimal metabolism in humans (Fujino et al., 2003). Therefore, BCRP is estimated to be involved in the biliary excretion of pitavastatin in humans. On the other hand, a previous in vivo study using EHBRs revealed that Mrp2 is a major transporter for the excretion of pravastatin in rats (Yamazaki et al., 1997). Even though pitavastatin and pravastatin belong to the same category, HMG-CoA reductase inhibitors, it was interesting to find that pitavastatin and pravastatin are excreted into the bile by different efflux transport systems. In the brain and kidney, in which BCRP is expressed, and skeletal muscle, which is a target site of severe adverse effects of statins (rhabdomyolysis), these tissue concentrations were not significantly different between Bcrp1\((-/-)\) and control mice. Thus, Bcrp does not contribute to the distribution of pitavastatin in these tissues. BCRP was expressed not only in the liver, kidney, and brain, but also in the small intestine and mammary gland (Doyle and Ross, 2003). It has been demonstrated that BCRP critically modulates the absorption of certain drugs from the small intestine and transfer to milk (Adachi et al., 2004; Merino et al., 2005a). Further studies need to be clarified the importance of BCRP in the intestinal absorption and tissue distribution of a series of statins.

In Fig. 3, we clearly observed the vectorial basal-to-apical transport of pitavastatin across all of the double transfectants (OATP1B1/BCRP, OATP1B1/MDR1, and OATP1B1/MRP2) in contrast to that across the control and OATP1B1 single-transfected cells. The efflux transport clearance of pitavastatin normalized by the intracellular concentration did not differ much among MDR1, MRP2, and BCRP, the range being only 2-fold. In the case of pravastatin, we demonstrated previously that the efflux clearance of MRP2 was much higher than that of MDR1 and BCRP (Matsushima et al., 2005). Considering these facts, the relative contribution of MDR1 and BCRP to the biliary excretion of pitavastatin was larger than that of pravastatin. In the case of rats, the basal-to-apical flux of pitavastatin across the Oatp1b2/Mrp2 double transflectants was significantly higher than that across the Oatp1b2 single transfectants (Fig. 4). However, the ratio of basal-to-apical to apical-to-basal flux of pitavastatin in Oatp1b2/Mrp2 double-transfected cells divided by that in Oatp1b2 single-transfected cells was approximately 1.6, which was small in comparison with that of other substrates tested previously (Sasaki et al., 2004). Therefore, although pitavastatin is a substrate of rat Mrp2, the intrinsic efflux clearance of pitavastatin via rat Mrp2 seems to be relatively low.

The elimination of diolomotecan from plasma has been found to be delayed in patients with frequently observed SNP in BCRP (C421A/Q141K) (Sparreboom et al., 2004). Various reports suggested that this SNP affected the protein expression level of BCRP in the placenta without changing its intrinsic efflux clearance (Kondo et al., 2004; Kobayashi et al., 2005). On the other hand, both in vivo and in vitro studies revealed that the frequently observed haplotype OATP1B1*15 (N130D and V174A) reduced the nonrenal clearance of pravastatin (Nishizato et al., 2003; Iwai et al., 2004). We demonstrated previously that pitavastatin is taken up into hepatocytes mainly by OATP1B1 (Hirano et al., 2004). Taking these facts into consideration, further clinical studies are needed to investigate the effect of SNPs in OATP1B1 and BCRP on the pharmacokinetics of pitavastatin and to determine the importance of each transporter directly in humans.

In the present study, we have shown that pitavastatin is recognized by human and mouse BCRP in expression systems, and Bcrp is mainly involved in the biliary excretion of pitavastatin by knockout animals. BCRP can also accept other statins as a substrate, implying that it is important to

### TABLE 3

Pharmacokinetic parameters of pitavastatin during constant intravenous infusion into wild-type and Bcrp1\((-/-)\) mice

<table>
<thead>
<tr>
<th>Data</th>
<th>C\textsubscript{ss,plasma}</th>
<th>CL\textsubscript{total}</th>
<th>CL\textsubscript{bile/plasma}</th>
<th>CL\textsubscript{bile,liver}</th>
<th>Liver Concentration</th>
<th>K\textsubscript{p,liver}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild type</td>
<td>254 ± 21</td>
<td>20.1 ± 1.8</td>
<td>1.21 ± 0.43</td>
<td>0.364 ± 0.032</td>
<td>813 ± 196</td>
<td>3.34 ± 1.03</td>
</tr>
<tr>
<td>Bcrp1((-/-))</td>
<td>213 ± 22</td>
<td>24.2 ± 2.5</td>
<td>0.110 ± 0.02*</td>
<td>0.0293 ± 0.0036**</td>
<td>798 ± 124</td>
<td>3.94 ± 0.83</td>
</tr>
</tbody>
</table>

* P < 0.05, ** P < 0.01.

C\textsubscript{ss,plasma}, plasma steady-state concentration (mean of plasma concentration at 150 min); CL\textsubscript{total}, total plasma clearance obtained by dividing the infusion rate by C\textsubscript{ss,plasma}; CL\textsubscript{bile/plasma}, biliary clearance normalized by the plasma concentration; CL\textsubscript{bile,liver}, biliary clearance normalized by the liver concentration; K\textsubscript{p,liver}, K\textsubscript{p} value obtained by dividing the liver concentration by C\textsubscript{ss,plasma} (at 150 min).
estimate how the change of function and expression level of BCRP affects the pharmacokinetics of statins. In humans, because it is evident that pitavastatin is a substrate of BCRP, MRD1, and MRP2 by double transfectants, it will be important to estimate the contribution of each transporter to the biliary excretion of pitavastatin in humans.

Acknowledgments
We thank Dr. Alfred H Schinkel (The Netherlands Cancer Institute, the Netherlands) and Dr. Joho Jonker (The Sarah Lasker for Biostudies, San Diego, CA) for constructing Bcrp1−/− mice and giving us valuable comments, Dr. Piet Borst (The Netherlands Cancer Institute) for providing the MDCK II cells expressing MRP2 and MDR1, and Dr. Yoshihiro Miwa (University of Tsukuba, Tsukuba, Japan) for providing pEB6CAGMCS/SRZeo vector. We also thank Dr. Makoto Sasaki for constructing Oatp1b2/Mrp2 double-transfected cells and Chihiko Kondo for constructing human BCRP recombinant adenovirus. We also thank Sankyo Co., Ltd. (Tokyo, Japan) for providing radiolabeled pravastatin, Novartis Pharma K.K. (Basel, Switzerland) for providing radiolabeled fluvastatin, AstaZeneca PLC (London, UK), for providing radiolabeled rosuvastatin, and Kowa Co. Ltd. (Tokyo, Japan) for providing radiolabeled pitavastatin and unlabeled statins.

References


